Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo.
Many clinical trials have shown the effectiveness of platelet-antiaggregant drugs in the treatment of obliterative peripheral arteriopathy , both locally and in the system , by improving the claudication symptoms and by preventing major cardiovascular events . In this study we evaluated the effectiveness of a 24-week treatment with triflusal , a comparatively new inhibitor of platelet aggregation , in patients affected by chronic peripheral arteriopathy , comparing twice-daily oral doses of 300 mg triflusal with twice-daily placebo doses . The percentages of successes ( defined as a 40 % increase of total walking distance over the basal control ) were 63.6 % in the triflusal group ( 35/55 patients ) and 22.5 % in the placebo group ( 14/62 patients ) . Patients treated with triflusal showed a more important increase in total walking distance and in pain-free walking distance over the basal values than those treated with placebo , together with an improvement of the symptomatology correlated with claudication . Moreover , in the triflusal group there was an increase in the peak-flow recorded through strain-gauge plethysmography . In conclusion , triflusal significantly increased both the distance which could be walked and the clinical symptoms , presumably by improving microperfusion
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .